# Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

> **NCT04694781** · PHASE1 · COMPLETED · sponsor: **Lyvgen Biopharma Holdings Limited** · enrollment: 18 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** LVGN6051
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04694781
- **Lead sponsor:** Lyvgen Biopharma Holdings Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-14
- **Primary completion:** 2023-10-31
- **Final completion:** 2023-10-31
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04694781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04694781, "Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04694781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*